Diaphanous related formin 3 knockdown suppresses cell proliferation and metastasis of osteosarcoma cells

Zehua Zhang1, Fei Dai1, Fei Luo1

  • 1Department of Orthopaedics, First Affiliated Hospital, Army Medical University, No. 30 Gaotanyanzheng street, Chongqing, 400038, China.

Discover Oncology
|February 24, 2022
PubMed

Insights

Diaphanous related formin 3 (DIAPH3) is upregulated in osteosarcoma, promoting tumor growth and metastasis. Targeting DIAPH3 may offer a new therapeutic strategy for osteosarcoma patients.

Area of Science:

  • Oncology
  • Molecular Biology

Background:

  • Osteosarcoma is a life-threatening bone cancer in children and adolescents.
  • There is a critical need for novel biomarkers and targeted therapies for osteosarcoma.
  • Diaphanous related formin 3 (DIAPH3) is implicated in other cancers, but its role in osteosarcoma is unknown.

Purpose of the Study:

  • To investigate the role and potential therapeutic significance of DIAPH3 in osteosarcoma.

Main Methods:

  • Immunohistochemical staining to assess DIAPH3 protein expression in osteosarcoma tissues.
  • Analysis of DIAPH3 mRNA expression correlation with patient survival outcomes.
  • In vitro knockdown experiments in osteosarcoma cell lines (MG-63, HOS) to evaluate proliferation, migration, and invasion.
  • In vivo studies using xenograft models to assess tumor growth and metastasis.

Main Results:

  • DIAPH3 protein is upregulated in osteosarcoma tissues.
  • Higher DIAPH3 expression correlates with advanced tumor stage, metastasis, and poorer survival.
  • DIAPH3 knockdown inhibited osteosarcoma cell proliferation, migration, and invasion in vitro.
  • DIAPH3 knockdown suppressed tumor growth and lung metastasis in vivo.

Conclusions:

  • DIAPH3 expression serves as a predictive biomarker for osteosarcoma clinical outcomes.
  • DIAPH3 plays a significant role in osteosarcoma proliferation and metastasis.
  • DIAPH3 represents a potential therapeutic target for osteosarcoma treatment.

Related Concept Videos